NASDAQ:VXRTVaxart Stock Price, Forecast & News

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VXRT stock has increased by 344.0% and is now trading at $9.19.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vaxart.

Vaxart is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Vaxart.

Vaxart Inc (NASDAQ:VXRT) posted its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.06. Vaxart had a negative net margin of 281.50% and a negative return on equity of 104.25%.
View Vaxart's earnings history.

Vaxart shares reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

3 brokers have issued 12-month target prices for Vaxart's stock. Their forecasts range from $6.00 to $22.00. On average, they expect Vaxart's stock price to reach $11.67 in the next year. This suggests a possible upside of 26.9% from the stock's current price.
View analysts' price targets for Vaxart.

Media stories about VXRT stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vaxart earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Vaxart.

Some companies that are related to Vaxart include Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), Denali Therapeutics (DNLI), Sorrento Therapeutics (SRNE), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), Legend Biotech (PCVX) and Bill.com (RVMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), VBI Vaccines (VBIV), Conatus Pharmaceuticals (CNAT), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), Agile Therapeutics (AGRX) and Co-Diagnostics (CODX).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by many different institutional and retail investors. Top institutional investors include UBS Group AG (0.28%), Hussman Strategic Advisors Inc. (0.18%), Russell Investments Group Ltd. (0.04%), National Asset Management Inc. (0.04%), Rathbone Brothers plc (0.04%) and New York State Common Retirement Fund (0.04%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

VXRT stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, and Todd C Davis.
View insider buying and selling activity for Vaxart.

VXRT stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Russell Investments Group Ltd., National Asset Management Inc., Rathbone Brothers plc, New York State Common Retirement Fund, Cambridge Investment Research Advisors Inc., SG Americas Securities LLC, and Edmond DE Rothschild Holding S.A.. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart.

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $9.19.

Vaxart has a market capitalization of $1.00 billion and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

The official website for Vaxart is www.vaxart.com.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]